Reader feedback universally says that off my
shortage story yesterday we should be buying
. I have bounced it off the team, but we all feel that AMD took away the upside by preannouncing a better first quarter.
To refresh, if Intel is having problems meeting demand for midlevel central processing units, then it is time to buy AMD, because AMD is not similarly supply constrained. This is one of those ideas that I would rather share with the site -- which is where I got the Intel-shortage piece of the puzzle -- than do myself.
Away from the chip stocks I see wide acceptance of everything that is four letters that is B2B -- just take a look at the
rotisserie league bulletin boards for those winners -- and, get this, some sellers of biotech, at last.
Amazing, the true secret behind the success of the biotech move is that it happened so fast the insiders haven't had a chance to register stock yet. Now that's what I call demand with no supply.
James J. Cramer is manager of a hedge fund and co-founder of TheStreet.com. At time of publication, his fund was long Intel. His fund often buys and sells securities that are the subject of his columns, both before and after the columns are published, and the positions that his fund takes may change at any time. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Cramer's writings provide insights into the dynamics of money management and are not a solicitation for transactions. While he cannot provide investment advice or recommendations, he invites you to comment on his column at